Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer

Ovarian cancer is one of the tumors with the highest fatality rate among gynecological tumors. The current 5-year survival rate of ovarian cancer is

Saved in:
Bibliographic Details
Published in:International journal of biological sciences 2024, Vol.20 (2), p.486-501
Main Authors: Wu, Min, Xie, Jiuqing, Xing, Yajing, Zhang, Lin, Chen, Huang, Tang, Bin, Zhou, Miaoran, Lv, Shiyi, Huang, Dongxia, Jian, Shuyi, Zhou, Cili, Liu, Mingyao, Guo, Weikai, Chen, Yihua, Yi, Zhengfang
Format: Article
Language:English
Subjects:
Animals
Cell Line, Tumor
Cisplatin - pharmacology
Cisplatin - therapeutic use
Female
Humans
Mice
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Proto-Oncogene Proteins c-bcl-6 - genetics
Proto-Oncogene Proteins c-bcl-6 - metabolism
Research Paper
Transcription Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer is one of the tumors with the highest fatality rate among gynecological tumors. The current 5-year survival rate of ovarian cancer is
ISSN:1449-2288
1449-2288
DOI:10.7150/ijbs.86303